research use only

Lesinurad sodium OAT inhibitor

Name: Lesinurad sodium
Brand: Selleck Chemicals
SKU: S5189
Rating: 5 (1 reviews)

Cat.No.S5189

Lesinurad (RDEA-594) sodium is a selective uric acid reabsorption inhibitor (SURI) under investigation for treatment of gout. Lesinurad sodium inhibits the uric acid transporter URAT1 and Kidney transporter OAT with IC50/Km of 4.3 Hm/0.85 Hm and 3.5 Hm/2 Hm for OAT1 and OAT3, respectively.

Chemical Structure

Molecular Weight: 426.26

Jump to

Quality Control

Batch: S518901 DMSO]85 mg/mL]false]Ethanol]85 mg/mL]false]Water]8 mg/mL]false Purity: 99.96%

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

99.96

Related Targets	CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase
Other OAT Inhibitors	Verinurad (RDEA3170) Dotinurad

Chemical Information, Storage & Stability

Molecular Weight	426.26	Formula	C₁₇H₁₃BrN₃NaO₂S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1151516-14-1	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	RDEA-594 sodium			Smiles	[Na+].[O-]C(=O)CSC1=NN=C(Br)[N]1C2=CC=C(C3CC3)C4=CC=CC=C24

Solubility

In vitro
Batch:

DMSO : 85 mg/mL (199.4 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 85 mg/mL

Water : 8 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	URAT1 OAT1 (Cell-free assay) 0.85 μM(Km) OAT3 (Cell-free assay) 2 μM(Km) OAT3 (Cell-free assay) 3.5 μM OAT1 (Cell-free assay) 4.3 μM
In vivo	Lesinurad, a pan-SLC22A inhibitor, reduces epithelial-mesenchymal transition (EMT)-induced metastasis and gemcitabine chemoresistance to prolong survival in mouse models of pancreatic cancer, thus identifying new vulnerabilities for human pancreatic ductal adenocarcinoma (PDAC).
References	[1] https://pubmed.ncbi.nlm.nih.gov/26951201/ [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036131/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04435782	Terminated	Pulmonary Arterial Hypertension	Actelion	July 7 2021	Phase 4
NCT04565990	Completed	Hypertension Pulmonary	Actelion	May 3 2021	Phase 3
NCT04175600	Active not recruiting	Hypertension Pulmonary	Actelion	January 16 2020	Phase 3
NCT03492177	Active not recruiting	Pulmonary Arterial Hypertension	Actelion	July 23 2018	Phase 2
NCT03496506	Completed	Healthy Subjects	Actelion	March 5 2018	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):